basal cell carcinoma from the molecular understanding of the pathogenesis to targeted therapy of progressive disease基底细胞癌的分子发病机制的理解进步疾病的靶向治疗.pdfVIP

Hindawi Publishing Corporation Journal of Skin Cancer Volume 2011, Article ID 650258, 8 pages doi:10.1155/2011/650258 Review Article Basal Cell Carcinoma: From the Molecular Understanding of the Pathogenesis to Targeted Therapy of Progressive Disease ¨ 1 2 Daniela Goppner and Martin Leverkus 1 Department of Dermatology and Venerology, Otto-von-Guericke-University Magdeburg, Leipziger St. 44, 39120 Magdeburg, Germany 2 Department of Dermatology, Venerology, and Allergology, Medical Faculty Mannheim, Ruprecht-Karls-University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany Correspondence should be addressed to Martin Leverkus, Martin.Leverkus@medma.uni-heidelberg.de Received 8 July 2010; Accepted 21 September 2010 Academic Editor: Torello Lotti ¨ Copyright © 2011 D. Goppner and M. Leverkus. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Due to intensified research over the past decade, the Hedgehog (HH) pathway has been identified as a pivotal defect implicated in roughly 25% of all cancers. As one of the most frequent cancer worldwide, the development of Basal cell carcinoma (BCC) due to activation of the HH pathway has been convincingly demonstrated. Thus the discovery of this central tumor-promoting signalling pathway has not only revolutionized the understanding of BCC carcinogenesis but has also enabled the development of a completely novel therapeutic approach. Targeting just a few of several potential mutations, HH inhibitors such as GDC- 0449 achiev